“…Cell Therapies for Cutaneous Regenerative Medicine Sub-optimal pharmacotherapeutic management of severe and complex cutaneous affections and complications (e.g., chronic ulcers, burns, donor-site wounds) has prompted the development of numerous skin graft solutions (e.g., amniotic membrane, cadaver grafts, fish skin), innovative bioengineered cellular therapy solutions (e.g., cultured autografts), or autologous and allogenic cell-based products (e.g., Allox R , Apligraf R , Epicel R , Lyphoderm R , OrCel R , ReCell R , TransCyte TM ) that complement surgical care and support tissue structural integrity and functional recovery (Lukish et al, 2001;Limat and Hunziker, 2002;Kumar et al, 2004;Amani et al, 2006;Hartmann et al, 2007;Zaulyanov and Kirsner, 2007;Akita et al, 2008;Hirt-Burri et al, 2008b;Guerid et al, 2013;Zuliani et al, 2013;Malhotra and Jain, 2014;Tan et al, 2014;Debels et al, 2015;Akershoek et al, 2016;Abdel-Sayed et al, 2019b;Lima-Junior et al, 2019;Momeni et al, 2019;Climov et al, 2020). Further optimization of biological starting materials for such advanced solutions may primarily benefit FIGURE 5 | Differential overview highlighting the similarities and differences between stem cells and primary FPC types.…”